newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

  • Ascentage Pharma Group International will present four preclinical studies in poster format at the AACR 2026 Annual Meeting held April 17-22, 2026, in San Diego, CA.
  • The presentations cover three drug candidates: Olverembatinib (HQP1351), APG-2449, & APG-5918.
  • Olverembatinib demonstrated efficacy & synergy with chemotherapy in preclinical endometrial carcinoma models by suppressing FGFR2, PI3K/AKT, & MEK/ERK pathways.
  • Olverembatinib showed synergistic effects with the BTK inhibitor acalabrutinib in mantle cell lymphoma models, inhibiting Lyn phosphorylation & downregulating NF-kB activity.
  • APG-2449 enhanced the antitumor activity of BRAF & MEK inhibitors in BRAF V600E-mutant colorectal cancer & melanoma models by suppressing compensatory signaling.
  • APG-5918 synergized with topoisomerase I inhibitors in small-cell lung cancer models by reducing H3K27me3 marks & increasing SLFN11 expression to reverse epigenetic silencing.
  • Olverembatinib is currently approved in China for CML but remains under investigation for other indications & in global Phase III trials including POLARIS-1, POLARIS-2, & POLARIS-3.
  • Lisaftoclax, a Bcl-2 inhibitor approved in China for CLL/SLL, is being evaluated in four global registrational Phase III trials including GLORA-1 through GLORA-4.
  • The company maintains global partnerships with major pharmaceutical entities such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent.